|

CD19/CD22/BCMA CAR-T cells(BZE2204) Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • Shanghai Cell Therapy Group Co.,Ltd1

Indications

  • Immune Thrombocytopenia (ITP)1
  • Idiopathic Inflammatory Myopathies(IIM)1
  • Systemic Lupus Erythematosus (SLE)1
  • Lupus1

Other1 trial

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.